This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): intravenous fludarabine phosphate
Description: BioMedTracker has separate drug profiles for the oral and IV formulationsof Fludara. Please also see Fludara Oral.
Fludara for injection contains Fludarabine phosphate, a purine analog. In dividing cells, purine analogs act to inhibit ribonucleotide reductase which results in the inhibition of DNA synthesis while in resting cells, they cause DNA strand breaks which results in cell death (apoptosis).
Deal Structure: In 2006, Bayer acquired Schering AG.
On March 31, 2009, Genzyme announced that it entered into an agreement to acquire Fludara, Leukine, and Campath/MabCampath from Bayer. The transaction was completed in June 2009.
In October 2010, Sanofi-aventis announced it has commenced a tender offer for all outstanding shares of common stock of Genzyme for $69 per share, net to the seller in cash, without interest and less any required withholding taxes. In April 2011, Sanofi-aventis announced that it successfully completed its exchange offer for all outstanding shares of common stock of Genzyme Corporation.
Fludara IV News
Pink Sheet FDA’s Oncologic Drugs Advisory Committee
Additional information available to subscribers only: